Aegis Positive on SciClone (SCLN) on Confirmed FY14 Guidance; Still Sees Zadaxin as Growth Driver
Tweet Send to a Friend
Aegis Capital affirms SciClone Pharmaceuticals (Nasdaq: SCLN) at Buy with a price target of $10 following reconfirmed FY14 guidance issued ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
